CN Patent

CN115279376A — 用于治疗异常细胞生长的组合疗法

Assigned to Verastem Inc · Expires 2022-11-01 · 4y expired

What this patent protects

本发明涉及KRAS G12C抑制剂与FAK抑制剂和/或MEK抑制剂或双重RAF/MEK抑制剂的组合的方法、组合物和口服剂型，其用于治疗异常细胞生长(例如，癌症)。

USPTO Abstract

本发明涉及KRAS G12C抑制剂与FAK抑制剂和/或MEK抑制剂或双重RAF/MEK抑制剂的组合的方法、组合物和口服剂型，其用于治疗异常细胞生长(例如，癌症)。

Drugs covered by this patent

Patent Metadata

Patent number
CN115279376A
Jurisdiction
CN
Classification
—
Expires
2022-11-01
Drug substance claim
No
Drug product claim
No
Assignee
Verastem Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.